nodes	percent_of_prediction	percent_of_DWPC	metapath
Tacrolimus—CYP3A7-CYP3A51P—Vincristine—muscle cancer	0.0697	0.141	CbGbCtD
Tacrolimus—CYP3A7—Vincristine—muscle cancer	0.0697	0.141	CbGbCtD
Tacrolimus—ABCB1—Dactinomycin—muscle cancer	0.0553	0.112	CbGbCtD
Tacrolimus—CYP3A5—Vincristine—muscle cancer	0.0523	0.106	CbGbCtD
Tacrolimus—CYP3A5—Etoposide—muscle cancer	0.0479	0.0972	CbGbCtD
Tacrolimus—ALB—Methotrexate—muscle cancer	0.0394	0.0799	CbGbCtD
Tacrolimus—ABCB1—Vincristine—muscle cancer	0.034	0.069	CbGbCtD
Tacrolimus—ABCB1—Etoposide—muscle cancer	0.0312	0.0632	CbGbCtD
Tacrolimus—ABCB1—Doxorubicin—muscle cancer	0.0213	0.0431	CbGbCtD
Tacrolimus—ABCB1—Methotrexate—muscle cancer	0.0206	0.0418	CbGbCtD
Tacrolimus—CYP3A4—Vincristine—muscle cancer	0.0204	0.0413	CbGbCtD
Tacrolimus—CYP3A4—Etoposide—muscle cancer	0.0187	0.0379	CbGbCtD
Tacrolimus—CYP3A4—Doxorubicin—muscle cancer	0.0127	0.0258	CbGbCtD
Tacrolimus—MTOR—hindlimb—muscle cancer	0.012	0.11	CbGeAlD
Tacrolimus—MTOR—appendage—muscle cancer	0.0103	0.0944	CbGeAlD
Tacrolimus—ABCA5—cardiac atrium—muscle cancer	0.00464	0.0426	CbGeAlD
Tacrolimus—ABCA5—tendon—muscle cancer	0.00405	0.0371	CbGeAlD
Tacrolimus—ABCA5—bone marrow—muscle cancer	0.00392	0.036	CbGeAlD
Tacrolimus—ABCA5—vagina—muscle cancer	0.00376	0.0344	CbGeAlD
Tacrolimus—PPP3CA—smooth muscle tissue—muscle cancer	0.00364	0.0334	CbGeAlD
Tacrolimus—PPP3CA—renal system—muscle cancer	0.0035	0.0321	CbGeAlD
Tacrolimus—ABCA5—head—muscle cancer	0.00347	0.0318	CbGeAlD
Tacrolimus—MTOR—embryo—muscle cancer	0.00342	0.0313	CbGeAlD
Tacrolimus—ABCA5—testis—muscle cancer	0.00335	0.0307	CbGeAlD
Tacrolimus—PPP3CA—cardiac atrium—muscle cancer	0.00314	0.0288	CbGeAlD
Tacrolimus—PPP3CA—tendon—muscle cancer	0.00273	0.0251	CbGeAlD
Tacrolimus—MTOR—smooth muscle tissue—muscle cancer	0.00269	0.0246	CbGeAlD
Tacrolimus—PPP3CA—bone marrow—muscle cancer	0.00265	0.0243	CbGeAlD
Tacrolimus—MTOR—renal system—muscle cancer	0.00259	0.0237	CbGeAlD
Tacrolimus—PPP3CA—vagina—muscle cancer	0.00254	0.0233	CbGeAlD
Tacrolimus—FKBP1A—smooth muscle tissue—muscle cancer	0.00242	0.0222	CbGeAlD
Tacrolimus—PPP3CA—head—muscle cancer	0.00234	0.0215	CbGeAlD
Tacrolimus—FKBP1A—renal system—muscle cancer	0.00233	0.0213	CbGeAlD
Tacrolimus—PPP3CA—testis—muscle cancer	0.00226	0.0208	CbGeAlD
Tacrolimus—FKBP1A—cardiac atrium—muscle cancer	0.00208	0.0191	CbGeAlD
Tacrolimus—MTOR—tendon—muscle cancer	0.00202	0.0185	CbGeAlD
Tacrolimus—MTOR—bone marrow—muscle cancer	0.00196	0.0179	CbGeAlD
Tacrolimus—MTOR—vagina—muscle cancer	0.00187	0.0172	CbGeAlD
Tacrolimus—FKBP1A—tendon—muscle cancer	0.00182	0.0167	CbGeAlD
Tacrolimus—FKBP1A—bone marrow—muscle cancer	0.00176	0.0161	CbGeAlD
Tacrolimus—MTOR—head—muscle cancer	0.00173	0.0159	CbGeAlD
Tacrolimus—FKBP1A—vagina—muscle cancer	0.00169	0.0155	CbGeAlD
Tacrolimus—MTOR—testis—muscle cancer	0.00167	0.0153	CbGeAlD
Tacrolimus—FKBP1A—head—muscle cancer	0.00156	0.0143	CbGeAlD
Tacrolimus—FKBP1A—testis—muscle cancer	0.0015	0.0138	CbGeAlD
Tacrolimus—ORM1—bone marrow—muscle cancer	0.00138	0.0126	CbGeAlD
Tacrolimus—ALB—testis—muscle cancer	0.00103	0.00947	CbGeAlD
Tacrolimus—CYP3A5—renal system—muscle cancer	0.00101	0.00929	CbGeAlD
Tacrolimus—CYP3A4—renal system—muscle cancer	0.00076	0.00697	CbGeAlD
Tacrolimus—CYP3A5—vagina—muscle cancer	0.000734	0.00673	CbGeAlD
Tacrolimus—ABCB1—embryo—muscle cancer	0.000711	0.00652	CbGeAlD
Tacrolimus—ABCB1—renal system—muscle cancer	0.000538	0.00494	CbGeAlD
Tacrolimus—CYP3A5—Constitutive Androstane Receptor Pathway—FOXO1—muscle cancer	0.000527	0.00747	CbGpPWpGaD
Tacrolimus—MTOR—PI-3K cascade—FOXO4—muscle cancer	0.000511	0.00724	CbGpPWpGaD
Tacrolimus—MTOR—PI3K/AKT activation—FOXO4—muscle cancer	0.000499	0.00706	CbGpPWpGaD
Tacrolimus—MTOR—GAB1 signalosome—FOXO4—muscle cancer	0.000495	0.00701	CbGpPWpGaD
Tacrolimus—MTOR—Role of LAT2/NTAL/LAB on calcium mobilization—FOXO4—muscle cancer	0.000484	0.00685	CbGpPWpGaD
Tacrolimus—MTOR—Leptin signaling pathway—FOXO1—muscle cancer	0.000468	0.00662	CbGpPWpGaD
Tacrolimus—MTOR—IRS-related events triggered by IGF1R—IGF2—muscle cancer	0.000443	0.00627	CbGpPWpGaD
Tacrolimus—PPP3CA—Spinal Cord Injury—PTGS2—muscle cancer	0.000432	0.00611	CbGpPWpGaD
Tacrolimus—MTOR—IGF1R signaling cascade—IGF2—muscle cancer	0.000432	0.00611	CbGpPWpGaD
Tacrolimus—MTOR—CXCR4-mediated signaling events—FOXO1—muscle cancer	0.000427	0.00605	CbGpPWpGaD
Tacrolimus—MTOR—Constitutive PI3K/AKT Signaling in Cancer—FOXO1—muscle cancer	0.000419	0.00593	CbGpPWpGaD
Tacrolimus—PPP3CA—Fc epsilon receptor (FCERI) signaling—KIT—muscle cancer	0.000411	0.00582	CbGpPWpGaD
Tacrolimus—ABCB1—bone marrow—muscle cancer	0.000407	0.00373	CbGeAlD
Tacrolimus—ABCB1—Constitutive Androstane Receptor Pathway—FOXO1—muscle cancer	0.000398	0.00563	CbGpPWpGaD
Tacrolimus—ABCB1—vagina—muscle cancer	0.00039	0.00358	CbGeAlD
Tacrolimus—MTOR—Signaling by SCF-KIT—FOXO4—muscle cancer	0.000382	0.00541	CbGpPWpGaD
Tacrolimus—MTOR—PI-3K cascade—FOXO1—muscle cancer	0.000378	0.00535	CbGpPWpGaD
Tacrolimus—MTOR—BDNF signaling pathway—CNR1—muscle cancer	0.000369	0.00522	CbGpPWpGaD
Tacrolimus—MTOR—PI3K/AKT activation—FOXO1—muscle cancer	0.000369	0.00522	CbGpPWpGaD
Tacrolimus—MTOR—GAB1 signalosome—FOXO1—muscle cancer	0.000366	0.00518	CbGpPWpGaD
Tacrolimus—MTOR—Downstream signaling of activated FGFR—FOXO4—muscle cancer	0.000366	0.00518	CbGpPWpGaD
Tacrolimus—MTOR—ErbB Signaling Pathway—MDM2—muscle cancer	0.000365	0.00517	CbGpPWpGaD
Tacrolimus—ABCB1—head—muscle cancer	0.00036	0.0033	CbGeAlD
Tacrolimus—MTOR—Signaling by ERBB4—FOXO4—muscle cancer	0.00036	0.00509	CbGpPWpGaD
Tacrolimus—MTOR—Role of LAT2/NTAL/LAB on calcium mobilization—FOXO1—muscle cancer	0.000357	0.00506	CbGpPWpGaD
Tacrolimus—PPP3CA—Alzheimers Disease—TP53—muscle cancer	0.000354	0.00501	CbGpPWpGaD
Tacrolimus—ABCB1—testis—muscle cancer	0.000348	0.00319	CbGeAlD
Tacrolimus—MTOR—Downstream signal transduction—FOXO4—muscle cancer	0.000344	0.00487	CbGpPWpGaD
Tacrolimus—MTOR—Signaling by FGFR—FOXO4—muscle cancer	0.000342	0.00484	CbGpPWpGaD
Tacrolimus—MTOR—EGF/EGFR Signaling Pathway—FOXO4—muscle cancer	0.000342	0.00484	CbGpPWpGaD
Tacrolimus—MTOR—Signaling by ERBB2—FOXO4—muscle cancer	0.00034	0.00482	CbGpPWpGaD
Tacrolimus—MTOR—DAP12 signaling—FOXO4—muscle cancer	0.000339	0.00479	CbGpPWpGaD
Tacrolimus—FKBP1A—Spinal Cord Injury—PTGS2—muscle cancer	0.000335	0.00474	CbGpPWpGaD
Tacrolimus—MTOR—Downstream signaling events of B Cell Receptor (BCR)—FOXO4—muscle cancer	0.000334	0.00472	CbGpPWpGaD
Tacrolimus—PPP3CA—Fc epsilon receptor (FCERI) signaling—MDM2—muscle cancer	0.000324	0.00458	CbGpPWpGaD
Tacrolimus—MTOR—Constitutive PI3K/AKT Signaling in Cancer—KIT—muscle cancer	0.000319	0.00452	CbGpPWpGaD
Tacrolimus—MTOR—Fc epsilon receptor (FCERI) signaling—FOXO4—muscle cancer	0.000319	0.00451	CbGpPWpGaD
Tacrolimus—MTOR—Signaling by FGFR in disease—FOXO4—muscle cancer	0.000319	0.00451	CbGpPWpGaD
Tacrolimus—MTOR—DAP12 interactions—FOXO4—muscle cancer	0.000319	0.00451	CbGpPWpGaD
Tacrolimus—PPP3CA—Signaling Pathways—KIDINS220—muscle cancer	0.000316	0.00447	CbGpPWpGaD
Tacrolimus—MTOR—Signaling by EGFR—FOXO4—muscle cancer	0.000316	0.00447	CbGpPWpGaD
Tacrolimus—MTOR—Signaling by EGFR in Cancer—FOXO4—muscle cancer	0.000313	0.00443	CbGpPWpGaD
Tacrolimus—MTOR—Signaling by PDGF—FOXO4—muscle cancer	0.000312	0.00441	CbGpPWpGaD
Tacrolimus—MTOR—B Cell Activation—FOXO4—muscle cancer	0.000295	0.00417	CbGpPWpGaD
Tacrolimus—MTOR—PI-3K cascade—KIT—muscle cancer	0.000288	0.00407	CbGpPWpGaD
Tacrolimus—PPP3CA—Innate Immune System—FOXO4—muscle cancer	0.000284	0.00402	CbGpPWpGaD
Tacrolimus—MTOR—Signaling by SCF-KIT—FOXO1—muscle cancer	0.000282	0.004	CbGpPWpGaD
Tacrolimus—MTOR—NGF signalling via TRKA from the plasma membrane—FOXO4—muscle cancer	0.000282	0.00399	CbGpPWpGaD
Tacrolimus—MTOR—PI3K/AKT activation—KIT—muscle cancer	0.000281	0.00398	CbGpPWpGaD
Tacrolimus—MTOR—GAB1 signalosome—KIT—muscle cancer	0.000279	0.00394	CbGpPWpGaD
Tacrolimus—MTOR—Role of LAT2/NTAL/LAB on calcium mobilization—KIT—muscle cancer	0.000272	0.00385	CbGpPWpGaD
Tacrolimus—MTOR—Downstream signaling of activated FGFR—FOXO1—muscle cancer	0.00027	0.00382	CbGpPWpGaD
Tacrolimus—MTOR—Integrated Breast Cancer Pathway—FOXO1—muscle cancer	0.000267	0.00378	CbGpPWpGaD
Tacrolimus—MTOR—Signaling by ERBB4—FOXO1—muscle cancer	0.000266	0.00376	CbGpPWpGaD
Tacrolimus—MTOR—Cellular responses to stress—HMGA1—muscle cancer	0.000258	0.00365	CbGpPWpGaD
Tacrolimus—PPP3CA—Spinal Cord Injury—TP53—muscle cancer	0.000257	0.00364	CbGpPWpGaD
Tacrolimus—MTOR—Insulin Signaling—FOXO1—muscle cancer	0.000255	0.00361	CbGpPWpGaD
Tacrolimus—MTOR—Downstream signal transduction—FOXO1—muscle cancer	0.000254	0.00359	CbGpPWpGaD
Tacrolimus—MTOR—EGF/EGFR Signaling Pathway—FOXO1—muscle cancer	0.000253	0.00358	CbGpPWpGaD
Tacrolimus—MTOR—Signaling by FGFR—FOXO1—muscle cancer	0.000253	0.00358	CbGpPWpGaD
Tacrolimus—MTOR—Constitutive PI3K/AKT Signaling in Cancer—MDM2—muscle cancer	0.000252	0.00356	CbGpPWpGaD
Tacrolimus—MTOR—Signaling by ERBB2—FOXO1—muscle cancer	0.000251	0.00356	CbGpPWpGaD
Tacrolimus—MTOR—LKB1 signaling events—TP53—muscle cancer	0.000251	0.00356	CbGpPWpGaD
Tacrolimus—MTOR—DAP12 signaling—FOXO1—muscle cancer	0.00025	0.00354	CbGpPWpGaD
Tacrolimus—MTOR—Downstream signaling events of B Cell Receptor (BCR)—FOXO1—muscle cancer	0.000246	0.00349	CbGpPWpGaD
Tacrolimus—CYP3A4—Constitutive Androstane Receptor Pathway—FOXO1—muscle cancer	0.000245	0.00347	CbGpPWpGaD
Tacrolimus—FKBP1A—Signaling Pathways—KIDINS220—muscle cancer	0.000245	0.00347	CbGpPWpGaD
Tacrolimus—PPP3CA—Immune System—CD34—muscle cancer	0.000243	0.00344	CbGpPWpGaD
Tacrolimus—MTOR—Oncostatin M Signaling Pathway—VEGFA—muscle cancer	0.000239	0.00338	CbGpPWpGaD
Tacrolimus—ALB—Platelet degranulation—IGF2—muscle cancer	0.000237	0.00336	CbGpPWpGaD
Tacrolimus—FKBP1A—Integrated Pancreatic Cancer Pathway—MDM2—muscle cancer	0.000236	0.00334	CbGpPWpGaD
Tacrolimus—MTOR—Signaling by FGFR in disease—FOXO1—muscle cancer	0.000235	0.00333	CbGpPWpGaD
Tacrolimus—MTOR—Fc epsilon receptor (FCERI) signaling—FOXO1—muscle cancer	0.000235	0.00333	CbGpPWpGaD
Tacrolimus—MTOR—DAP12 interactions—FOXO1—muscle cancer	0.000235	0.00333	CbGpPWpGaD
Tacrolimus—MTOR—Signaling by EGFR—FOXO1—muscle cancer	0.000233	0.0033	CbGpPWpGaD
Tacrolimus—MTOR—Signaling by EGFR in Cancer—FOXO1—muscle cancer	0.000231	0.00327	CbGpPWpGaD
Tacrolimus—MTOR—Signaling by PDGF—FOXO1—muscle cancer	0.00023	0.00326	CbGpPWpGaD
Tacrolimus—FKBP1A—Integrated Pancreatic Cancer Pathway—PTGS2—muscle cancer	0.000228	0.00322	CbGpPWpGaD
Tacrolimus—MTOR—PI-3K cascade—MDM2—muscle cancer	0.000227	0.00321	CbGpPWpGaD
Tacrolimus—ALB—Response to elevated platelet cytosolic Ca2+—IGF2—muscle cancer	0.000226	0.0032	CbGpPWpGaD
Tacrolimus—MTOR—PI3K/AKT activation—MDM2—muscle cancer	0.000221	0.00313	CbGpPWpGaD
Tacrolimus—MTOR—Senescence and Autophagy in Cancer—CDKN2A—muscle cancer	0.000221	0.00313	CbGpPWpGaD
Tacrolimus—MTOR—GAB1 signalosome—MDM2—muscle cancer	0.000219	0.00311	CbGpPWpGaD
Tacrolimus—MTOR—B Cell Activation—FOXO1—muscle cancer	0.000218	0.00308	CbGpPWpGaD
Tacrolimus—MTOR—Signaling by NGF—FOXO4—muscle cancer	0.000217	0.00307	CbGpPWpGaD
Tacrolimus—ABCB1—Imatinib Resistance in Chronic Myeloid Leukemia—KIT—muscle cancer	0.000216	0.00305	CbGpPWpGaD
Tacrolimus—MTOR—Signaling by SCF-KIT—KIT—muscle cancer	0.000215	0.00304	CbGpPWpGaD
Tacrolimus—MTOR—Role of LAT2/NTAL/LAB on calcium mobilization—MDM2—muscle cancer	0.000214	0.00304	CbGpPWpGaD
Tacrolimus—MTOR—Senescence and Autophagy in Cancer—MDM2—muscle cancer	0.000214	0.00304	CbGpPWpGaD
Tacrolimus—Skin disorder—Etoposide—muscle cancer	0.000213	0.00065	CcSEcCtD
Tacrolimus—Dry skin—Doxorubicin—muscle cancer	0.000212	0.000647	CcSEcCtD
Tacrolimus—Hyperhidrosis—Etoposide—muscle cancer	0.000212	0.000647	CcSEcCtD
Tacrolimus—Orthostatic hypotension—Doxorubicin—muscle cancer	0.000211	0.000645	CcSEcCtD
Tacrolimus—PPP3CA—Signaling by GPCR—PTCH1—muscle cancer	0.00021	0.00298	CbGpPWpGaD
Tacrolimus—Photosensitivity reaction—Methotrexate—muscle cancer	0.00021	0.000643	CcSEcCtD
Tacrolimus—Hypokalaemia—Doxorubicin—muscle cancer	0.00021	0.000643	CcSEcCtD
Tacrolimus—PPP3CA—Innate Immune System—FOXO1—muscle cancer	0.00021	0.00297	CbGpPWpGaD
Tacrolimus—MTOR—ErbB Signaling Pathway—TP53—muscle cancer	0.000209	0.00296	CbGpPWpGaD
Tacrolimus—Breast disorder—Doxorubicin—muscle cancer	0.000209	0.000638	CcSEcCtD
Tacrolimus—Anorexia—Etoposide—muscle cancer	0.000209	0.000638	CcSEcCtD
Tacrolimus—MTOR—NGF signalling via TRKA from the plasma membrane—FOXO1—muscle cancer	0.000208	0.00295	CbGpPWpGaD
Tacrolimus—Toxic epidermal necrolysis—Doxorubicin—muscle cancer	0.000208	0.000636	CcSEcCtD
Tacrolimus—Diarrhoea—Dactinomycin—muscle cancer	0.000207	0.000632	CcSEcCtD
Tacrolimus—Pneumonia—Methotrexate—muscle cancer	0.000207	0.000632	CcSEcCtD
Tacrolimus—MTOR—Downstream signaling of activated FGFR—KIT—muscle cancer	0.000206	0.00291	CbGpPWpGaD
Tacrolimus—Infestation—Methotrexate—muscle cancer	0.000205	0.000628	CcSEcCtD
Tacrolimus—Infestation NOS—Methotrexate—muscle cancer	0.000205	0.000628	CcSEcCtD
Tacrolimus—Depression—Methotrexate—muscle cancer	0.000205	0.000627	CcSEcCtD
Tacrolimus—Hypotension—Etoposide—muscle cancer	0.000204	0.000625	CcSEcCtD
Tacrolimus—Gastritis—Doxorubicin—muscle cancer	0.000204	0.000625	CcSEcCtD
Tacrolimus—Stevens-Johnson syndrome—Methotrexate—muscle cancer	0.000204	0.000623	CcSEcCtD
Tacrolimus—Muscular weakness—Doxorubicin—muscle cancer	0.000204	0.000623	CcSEcCtD
Tacrolimus—MTOR—Signaling by ERBB4—KIT—muscle cancer	0.000202	0.00287	CbGpPWpGaD
Tacrolimus—Renal failure—Methotrexate—muscle cancer	0.000202	0.000618	CcSEcCtD
Tacrolimus—Abdominal distension—Doxorubicin—muscle cancer	0.000201	0.000614	CcSEcCtD
Tacrolimus—Stomatitis—Methotrexate—muscle cancer	0.0002	0.000612	CcSEcCtD
Tacrolimus—Conjunctivitis—Methotrexate—muscle cancer	0.0002	0.000611	CcSEcCtD
Tacrolimus—Influenza—Doxorubicin—muscle cancer	0.0002	0.00061	CcSEcCtD
Tacrolimus—Asthma—Doxorubicin—muscle cancer	0.0002	0.00061	CcSEcCtD
Tacrolimus—Dysphagia—Doxorubicin—muscle cancer	0.0002	0.00061	CcSEcCtD
Tacrolimus—FKBP1A—Spinal Cord Injury—TP53—muscle cancer	0.000199	0.00282	CbGpPWpGaD
Tacrolimus—Hypersensitivity—Vincristine—muscle cancer	0.000199	0.000608	CcSEcCtD
Tacrolimus—Sweating—Methotrexate—muscle cancer	0.000197	0.000602	CcSEcCtD
Tacrolimus—Paraesthesia—Etoposide—muscle cancer	0.000196	0.000601	CcSEcCtD
Tacrolimus—Haematuria—Methotrexate—muscle cancer	0.000196	0.000599	CcSEcCtD
Tacrolimus—Pancreatitis—Doxorubicin—muscle cancer	0.000196	0.000598	CcSEcCtD
Tacrolimus—Dyspnoea—Etoposide—muscle cancer	0.000195	0.000596	CcSEcCtD
Tacrolimus—Somnolence—Etoposide—muscle cancer	0.000195	0.000595	CcSEcCtD
Tacrolimus—Angina pectoris—Doxorubicin—muscle cancer	0.000194	0.000594	CcSEcCtD
Tacrolimus—Hepatobiliary disease—Methotrexate—muscle cancer	0.000194	0.000594	CcSEcCtD
Tacrolimus—Epistaxis—Methotrexate—muscle cancer	0.000194	0.000593	CcSEcCtD
Tacrolimus—Asthenia—Vincristine—muscle cancer	0.000194	0.000593	CcSEcCtD
Tacrolimus—PPP3CA—MAPK Signaling Pathway—TP53—muscle cancer	0.000194	0.00274	CbGpPWpGaD
Tacrolimus—MTOR—Downstream signal transduction—KIT—muscle cancer	0.000193	0.00274	CbGpPWpGaD
Tacrolimus—MTOR—Signaling by FGFR—KIT—muscle cancer	0.000192	0.00272	CbGpPWpGaD
Tacrolimus—Vomiting—Dactinomycin—muscle cancer	0.000192	0.000588	CcSEcCtD
Tacrolimus—Bronchitis—Doxorubicin—muscle cancer	0.000192	0.000587	CcSEcCtD
Tacrolimus—Agranulocytosis—Methotrexate—muscle cancer	0.000192	0.000586	CcSEcCtD
Tacrolimus—MTOR—Signaling by ERBB2—KIT—muscle cancer	0.000191	0.00271	CbGpPWpGaD
Tacrolimus—Rash—Dactinomycin—muscle cancer	0.000191	0.000583	CcSEcCtD
Tacrolimus—MTOR—DAP12 signaling—KIT—muscle cancer	0.000191	0.0027	CbGpPWpGaD
Tacrolimus—Decreased appetite—Etoposide—muscle cancer	0.00019	0.000582	CcSEcCtD
Tacrolimus—Pancytopenia—Doxorubicin—muscle cancer	0.00019	0.00058	CcSEcCtD
Tacrolimus—Gastrointestinal disorder—Etoposide—muscle cancer	0.000189	0.000578	CcSEcCtD
Tacrolimus—Fatigue—Etoposide—muscle cancer	0.000189	0.000577	CcSEcCtD
Tacrolimus—MTOR—Downstream signaling events of B Cell Receptor (BCR)—KIT—muscle cancer	0.000188	0.00266	CbGpPWpGaD
Tacrolimus—PPP3CA—Disease—ENO2—muscle cancer	0.000187	0.00265	CbGpPWpGaD
Tacrolimus—Pain—Etoposide—muscle cancer	0.000187	0.000572	CcSEcCtD
Tacrolimus—Constipation—Etoposide—muscle cancer	0.000187	0.000572	CcSEcCtD
Tacrolimus—Dysuria—Doxorubicin—muscle cancer	0.000187	0.000571	CcSEcCtD
Tacrolimus—Neutropenia—Doxorubicin—muscle cancer	0.000187	0.000571	CcSEcCtD
Tacrolimus—Haemoglobin—Methotrexate—muscle cancer	0.000185	0.000567	CcSEcCtD
Tacrolimus—Diarrhoea—Vincristine—muscle cancer	0.000185	0.000565	CcSEcCtD
Tacrolimus—Haemorrhage—Methotrexate—muscle cancer	0.000184	0.000564	CcSEcCtD
Tacrolimus—Hepatitis—Methotrexate—muscle cancer	0.000184	0.000564	CcSEcCtD
Tacrolimus—Pollakiuria—Doxorubicin—muscle cancer	0.000184	0.000564	CcSEcCtD
Tacrolimus—Pharyngitis—Methotrexate—muscle cancer	0.000183	0.00056	CcSEcCtD
Tacrolimus—Urinary tract disorder—Methotrexate—muscle cancer	0.000182	0.000557	CcSEcCtD
Tacrolimus—Photosensitivity reaction—Doxorubicin—muscle cancer	0.000182	0.000557	CcSEcCtD
Tacrolimus—Weight increased—Doxorubicin—muscle cancer	0.000182	0.000555	CcSEcCtD
Tacrolimus—Urethral disorder—Methotrexate—muscle cancer	0.000181	0.000553	CcSEcCtD
Tacrolimus—Weight decreased—Doxorubicin—muscle cancer	0.000181	0.000552	CcSEcCtD
Tacrolimus—MTOR—Oncostatin M Signaling Pathway—TP53—muscle cancer	0.000181	0.00256	CbGpPWpGaD
Tacrolimus—Feeling abnormal—Etoposide—muscle cancer	0.00018	0.000551	CcSEcCtD
Tacrolimus—Hyperglycaemia—Doxorubicin—muscle cancer	0.00018	0.00055	CcSEcCtD
Tacrolimus—Nausea—Dactinomycin—muscle cancer	0.00018	0.000549	CcSEcCtD
Tacrolimus—FKBP1A—Integrated Pancreatic Cancer Pathway—VEGFA—muscle cancer	0.000179	0.00254	CbGpPWpGaD
Tacrolimus—MTOR—Signaling by FGFR in disease—KIT—muscle cancer	0.000179	0.00254	CbGpPWpGaD
Tacrolimus—MTOR—Fc epsilon receptor (FCERI) signaling—KIT—muscle cancer	0.000179	0.00254	CbGpPWpGaD
Tacrolimus—MTOR—DAP12 interactions—KIT—muscle cancer	0.000179	0.00254	CbGpPWpGaD
Tacrolimus—Pneumonia—Doxorubicin—muscle cancer	0.000179	0.000547	CcSEcCtD
Tacrolimus—Gastrointestinal pain—Etoposide—muscle cancer	0.000179	0.000547	CcSEcCtD
Tacrolimus—Dizziness—Vincristine—muscle cancer	0.000179	0.000546	CcSEcCtD
Tacrolimus—Infestation NOS—Doxorubicin—muscle cancer	0.000178	0.000544	CcSEcCtD
Tacrolimus—Infestation—Doxorubicin—muscle cancer	0.000178	0.000544	CcSEcCtD
Tacrolimus—Visual impairment—Methotrexate—muscle cancer	0.000178	0.000544	CcSEcCtD
Tacrolimus—MTOR—Signaling by EGFR—KIT—muscle cancer	0.000178	0.00252	CbGpPWpGaD
Tacrolimus—PPP3CA—Signaling by GPCR—CNR1—muscle cancer	0.000178	0.00251	CbGpPWpGaD
Tacrolimus—ABCB1—Integrated Pancreatic Cancer Pathway—WT1—muscle cancer	0.000176	0.0025	CbGpPWpGaD
Tacrolimus—Stevens-Johnson syndrome—Doxorubicin—muscle cancer	0.000176	0.000539	CcSEcCtD
Tacrolimus—MTOR—Signaling by EGFR in Cancer—KIT—muscle cancer	0.000176	0.00249	CbGpPWpGaD
Tacrolimus—MTOR—Signaling by PDGF—KIT—muscle cancer	0.000175	0.00248	CbGpPWpGaD
Tacrolimus—Renal failure—Doxorubicin—muscle cancer	0.000175	0.000535	CcSEcCtD
Tacrolimus—MTOR—Adaptive Immune System—CD34—muscle cancer	0.000175	0.00248	CbGpPWpGaD
Tacrolimus—Erythema multiforme—Methotrexate—muscle cancer	0.000174	0.000533	CcSEcCtD
Tacrolimus—Neuropathy peripheral—Doxorubicin—muscle cancer	0.000174	0.000533	CcSEcCtD
Tacrolimus—Urticaria—Etoposide—muscle cancer	0.000174	0.000531	CcSEcCtD
Tacrolimus—Jaundice—Doxorubicin—muscle cancer	0.000173	0.00053	CcSEcCtD
Tacrolimus—Stomatitis—Doxorubicin—muscle cancer	0.000173	0.00053	CcSEcCtD
Tacrolimus—Abdominal pain—Etoposide—muscle cancer	0.000173	0.000529	CcSEcCtD
Tacrolimus—Body temperature increased—Etoposide—muscle cancer	0.000173	0.000529	CcSEcCtD
Tacrolimus—Urinary tract infection—Doxorubicin—muscle cancer	0.000173	0.000529	CcSEcCtD
Tacrolimus—Conjunctivitis—Doxorubicin—muscle cancer	0.000173	0.000529	CcSEcCtD
Tacrolimus—Eye disorder—Methotrexate—muscle cancer	0.000172	0.000527	CcSEcCtD
Tacrolimus—MTOR—AMPK Signaling—TP53—muscle cancer	0.000172	0.00244	CbGpPWpGaD
Tacrolimus—Tinnitus—Methotrexate—muscle cancer	0.000172	0.000526	CcSEcCtD
Tacrolimus—Vomiting—Vincristine—muscle cancer	0.000172	0.000525	CcSEcCtD
Tacrolimus—Cardiac disorder—Methotrexate—muscle cancer	0.000171	0.000523	CcSEcCtD
Tacrolimus—Sweating—Doxorubicin—muscle cancer	0.000171	0.000522	CcSEcCtD
Tacrolimus—Rash—Vincristine—muscle cancer	0.00017	0.000521	CcSEcCtD
Tacrolimus—PPP3CA—Disease—HMGA1—muscle cancer	0.00017	0.00241	CbGpPWpGaD
Tacrolimus—Dermatitis—Vincristine—muscle cancer	0.00017	0.00052	CcSEcCtD
Tacrolimus—Haematuria—Doxorubicin—muscle cancer	0.00017	0.000519	CcSEcCtD
Tacrolimus—MTOR—Signaling by SCF-KIT—MDM2—muscle cancer	0.000169	0.0024	CbGpPWpGaD
Tacrolimus—Headache—Vincristine—muscle cancer	0.000169	0.000517	CcSEcCtD
Tacrolimus—Hepatobiliary disease—Doxorubicin—muscle cancer	0.000168	0.000515	CcSEcCtD
Tacrolimus—Epistaxis—Doxorubicin—muscle cancer	0.000168	0.000513	CcSEcCtD
Tacrolimus—Angiopathy—Methotrexate—muscle cancer	0.000167	0.000512	CcSEcCtD
Tacrolimus—Sinusitis—Doxorubicin—muscle cancer	0.000167	0.00051	CcSEcCtD
Tacrolimus—Immune system disorder—Methotrexate—muscle cancer	0.000167	0.000509	CcSEcCtD
Tacrolimus—Mediastinal disorder—Methotrexate—muscle cancer	0.000166	0.000508	CcSEcCtD
Tacrolimus—Agranulocytosis—Doxorubicin—muscle cancer	0.000166	0.000508	CcSEcCtD
Tacrolimus—MTOR—B Cell Activation—KIT—muscle cancer	0.000166	0.00235	CbGpPWpGaD
Tacrolimus—Chills—Methotrexate—muscle cancer	0.000166	0.000506	CcSEcCtD
Tacrolimus—PPP3CA—Immune System—FOXO4—muscle cancer	0.000165	0.00234	CbGpPWpGaD
Tacrolimus—Alopecia—Methotrexate—muscle cancer	0.000163	0.000498	CcSEcCtD
Tacrolimus—Bradycardia—Doxorubicin—muscle cancer	0.000163	0.000497	CcSEcCtD
Tacrolimus—MTOR—Downstream signaling of activated FGFR—MDM2—muscle cancer	0.000162	0.00229	CbGpPWpGaD
Tacrolimus—Mental disorder—Methotrexate—muscle cancer	0.000162	0.000494	CcSEcCtD
Tacrolimus—Hypersensitivity—Etoposide—muscle cancer	0.000161	0.000493	CcSEcCtD
Tacrolimus—Malnutrition—Methotrexate—muscle cancer	0.000161	0.000491	CcSEcCtD
Tacrolimus—Erythema—Methotrexate—muscle cancer	0.000161	0.000491	CcSEcCtD
Tacrolimus—Haemoglobin—Doxorubicin—muscle cancer	0.000161	0.000491	CcSEcCtD
Tacrolimus—Nausea—Vincristine—muscle cancer	0.00016	0.000491	CcSEcCtD
Tacrolimus—MTOR—VEGFA-VEGFR2 Pathway—VEGFA—muscle cancer	0.00016	0.00227	CbGpPWpGaD
Tacrolimus—MTOR—Integrated Breast Cancer Pathway—MDM2—muscle cancer	0.00016	0.00227	CbGpPWpGaD
Tacrolimus—MTOR—Signaling by NGF—FOXO1—muscle cancer	0.00016	0.00227	CbGpPWpGaD
Tacrolimus—Rhinitis—Doxorubicin—muscle cancer	0.00016	0.00049	CcSEcCtD
Tacrolimus—Haemorrhage—Doxorubicin—muscle cancer	0.00016	0.000488	CcSEcCtD
Tacrolimus—Hepatitis—Doxorubicin—muscle cancer	0.00016	0.000488	CcSEcCtD
Tacrolimus—PPP3CA—Innate Immune System—KIT—muscle cancer	0.00016	0.00226	CbGpPWpGaD
Tacrolimus—MTOR—Signaling by ERBB4—MDM2—muscle cancer	0.000159	0.00226	CbGpPWpGaD
Tacrolimus—Hypoaesthesia—Doxorubicin—muscle cancer	0.000159	0.000486	CcSEcCtD
Tacrolimus—MTOR—NGF signalling via TRKA from the plasma membrane—KIT—muscle cancer	0.000159	0.00225	CbGpPWpGaD
Tacrolimus—Pharyngitis—Doxorubicin—muscle cancer	0.000159	0.000485	CcSEcCtD
Tacrolimus—Urinary tract disorder—Doxorubicin—muscle cancer	0.000158	0.000482	CcSEcCtD
Tacrolimus—Oedema peripheral—Doxorubicin—muscle cancer	0.000157	0.000481	CcSEcCtD
Tacrolimus—Dysgeusia—Methotrexate—muscle cancer	0.000157	0.000481	CcSEcCtD
Tacrolimus—Asthenia—Etoposide—muscle cancer	0.000157	0.00048	CcSEcCtD
Tacrolimus—Connective tissue disorder—Doxorubicin—muscle cancer	0.000157	0.00048	CcSEcCtD
Tacrolimus—Urethral disorder—Doxorubicin—muscle cancer	0.000157	0.000479	CcSEcCtD
Tacrolimus—Back pain—Methotrexate—muscle cancer	0.000155	0.000475	CcSEcCtD
Tacrolimus—Pruritus—Etoposide—muscle cancer	0.000155	0.000473	CcSEcCtD
Tacrolimus—Visual impairment—Doxorubicin—muscle cancer	0.000154	0.000471	CcSEcCtD
Tacrolimus—PPP3CA—Disease—FOXO4—muscle cancer	0.000153	0.00216	CbGpPWpGaD
Tacrolimus—MTOR—Downstream signal transduction—MDM2—muscle cancer	0.000152	0.00216	CbGpPWpGaD
Tacrolimus—MTOR—Signaling by FGFR—MDM2—muscle cancer	0.000152	0.00215	CbGpPWpGaD
Tacrolimus—MTOR—Signaling by VEGF—VEGFA—muscle cancer	0.000151	0.00214	CbGpPWpGaD
Tacrolimus—Vision blurred—Methotrexate—muscle cancer	0.000151	0.000463	CcSEcCtD
Tacrolimus—Erythema multiforme—Doxorubicin—muscle cancer	0.000151	0.000462	CcSEcCtD
Tacrolimus—MTOR—Signaling by ERBB2—MDM2—muscle cancer	0.000151	0.00214	CbGpPWpGaD
Tacrolimus—MTOR—DAP12 signaling—MDM2—muscle cancer	0.00015	0.00212	CbGpPWpGaD
Tacrolimus—Diarrhoea—Etoposide—muscle cancer	0.00015	0.000458	CcSEcCtD
Tacrolimus—Eye disorder—Doxorubicin—muscle cancer	0.000149	0.000456	CcSEcCtD
Tacrolimus—Ill-defined disorder—Methotrexate—muscle cancer	0.000149	0.000456	CcSEcCtD
Tacrolimus—Tinnitus—Doxorubicin—muscle cancer	0.000149	0.000455	CcSEcCtD
Tacrolimus—Anaemia—Methotrexate—muscle cancer	0.000148	0.000454	CcSEcCtD
Tacrolimus—Flushing—Doxorubicin—muscle cancer	0.000148	0.000453	CcSEcCtD
Tacrolimus—Cardiac disorder—Doxorubicin—muscle cancer	0.000148	0.000453	CcSEcCtD
Tacrolimus—MTOR—Downstream signaling events of B Cell Receptor (BCR)—MDM2—muscle cancer	0.000148	0.00209	CbGpPWpGaD
Tacrolimus—FKBP1A—Disease—ENO2—muscle cancer	0.000145	0.00206	CbGpPWpGaD
Tacrolimus—Angiopathy—Doxorubicin—muscle cancer	0.000145	0.000443	CcSEcCtD
Tacrolimus—Malaise—Methotrexate—muscle cancer	0.000145	0.000443	CcSEcCtD
Tacrolimus—Dizziness—Etoposide—muscle cancer	0.000145	0.000442	CcSEcCtD
Tacrolimus—Immune system disorder—Doxorubicin—muscle cancer	0.000144	0.000441	CcSEcCtD
Tacrolimus—Vertigo—Methotrexate—muscle cancer	0.000144	0.000441	CcSEcCtD
Tacrolimus—Mediastinal disorder—Doxorubicin—muscle cancer	0.000144	0.00044	CcSEcCtD
Tacrolimus—Leukopenia—Methotrexate—muscle cancer	0.000144	0.00044	CcSEcCtD
Tacrolimus—Chills—Doxorubicin—muscle cancer	0.000143	0.000438	CcSEcCtD
Tacrolimus—Arrhythmia—Doxorubicin—muscle cancer	0.000143	0.000436	CcSEcCtD
Tacrolimus—MTOR—DAP12 interactions—MDM2—muscle cancer	0.000141	0.002	CbGpPWpGaD
Tacrolimus—MTOR—Fc epsilon receptor (FCERI) signaling—MDM2—muscle cancer	0.000141	0.002	CbGpPWpGaD
Tacrolimus—MTOR—Signaling by FGFR in disease—MDM2—muscle cancer	0.000141	0.002	CbGpPWpGaD
Tacrolimus—Alopecia—Doxorubicin—muscle cancer	0.000141	0.000432	CcSEcCtD
Tacrolimus—Cough—Methotrexate—muscle cancer	0.00014	0.000428	CcSEcCtD
Tacrolimus—Mental disorder—Doxorubicin—muscle cancer	0.00014	0.000428	CcSEcCtD
Tacrolimus—MTOR—Signaling by EGFR—MDM2—muscle cancer	0.00014	0.00198	CbGpPWpGaD
Tacrolimus—Convulsion—Methotrexate—muscle cancer	0.000139	0.000425	CcSEcCtD
Tacrolimus—Vomiting—Etoposide—muscle cancer	0.000139	0.000425	CcSEcCtD
Tacrolimus—Erythema—Doxorubicin—muscle cancer	0.000139	0.000425	CcSEcCtD
Tacrolimus—Malnutrition—Doxorubicin—muscle cancer	0.000139	0.000425	CcSEcCtD
Tacrolimus—MTOR—Signaling by EGFR in Cancer—MDM2—muscle cancer	0.000139	0.00196	CbGpPWpGaD
Tacrolimus—MTOR—Signaling by PDGF—MDM2—muscle cancer	0.000138	0.00195	CbGpPWpGaD
Tacrolimus—Rash—Etoposide—muscle cancer	0.000138	0.000422	CcSEcCtD
Tacrolimus—Dermatitis—Etoposide—muscle cancer	0.000138	0.000421	CcSEcCtD
Tacrolimus—MTOR—Signaling Pathways—KIDINS220—muscle cancer	0.000138	0.00195	CbGpPWpGaD
Tacrolimus—Headache—Etoposide—muscle cancer	0.000137	0.000419	CcSEcCtD
Tacrolimus—Flatulence—Doxorubicin—muscle cancer	0.000137	0.000419	CcSEcCtD
Tacrolimus—Chest pain—Methotrexate—muscle cancer	0.000137	0.000418	CcSEcCtD
Tacrolimus—Arthralgia—Methotrexate—muscle cancer	0.000137	0.000418	CcSEcCtD
Tacrolimus—Myalgia—Methotrexate—muscle cancer	0.000137	0.000418	CcSEcCtD
Tacrolimus—Tension—Doxorubicin—muscle cancer	0.000136	0.000417	CcSEcCtD
Tacrolimus—Dysgeusia—Doxorubicin—muscle cancer	0.000136	0.000416	CcSEcCtD
Tacrolimus—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—muscle cancer	0.000136	0.000415	CcSEcCtD
Tacrolimus—FKBP1A—Integrated Pancreatic Cancer Pathway—TP53—muscle cancer	0.000136	0.00192	CbGpPWpGaD
Tacrolimus—Discomfort—Methotrexate—muscle cancer	0.000135	0.000413	CcSEcCtD
Tacrolimus—Nervousness—Doxorubicin—muscle cancer	0.000135	0.000413	CcSEcCtD
Tacrolimus—Back pain—Doxorubicin—muscle cancer	0.000135	0.000411	CcSEcCtD
Tacrolimus—Muscle spasms—Doxorubicin—muscle cancer	0.000134	0.000409	CcSEcCtD
Tacrolimus—Confusional state—Methotrexate—muscle cancer	0.000132	0.000404	CcSEcCtD
Tacrolimus—FKBP1A—Disease—HMGA1—muscle cancer	0.000132	0.00187	CbGpPWpGaD
Tacrolimus—Anaphylactic shock—Methotrexate—muscle cancer	0.000131	0.000401	CcSEcCtD
Tacrolimus—Vision blurred—Doxorubicin—muscle cancer	0.000131	0.000401	CcSEcCtD
Tacrolimus—MTOR—B Cell Activation—MDM2—muscle cancer	0.000131	0.00185	CbGpPWpGaD
Tacrolimus—Infection—Methotrexate—muscle cancer	0.00013	0.000398	CcSEcCtD
Tacrolimus—Nausea—Etoposide—muscle cancer	0.00013	0.000397	CcSEcCtD
Tacrolimus—ABCB1—Integrated Pancreatic Cancer Pathway—BUB1B—muscle cancer	0.000129	0.00183	CbGpPWpGaD
Tacrolimus—Ill-defined disorder—Doxorubicin—muscle cancer	0.000129	0.000394	CcSEcCtD
Tacrolimus—Nervous system disorder—Methotrexate—muscle cancer	0.000129	0.000393	CcSEcCtD
Tacrolimus—Anaemia—Doxorubicin—muscle cancer	0.000129	0.000393	CcSEcCtD
Tacrolimus—Thrombocytopenia—Methotrexate—muscle cancer	0.000128	0.000392	CcSEcCtD
Tacrolimus—Agitation—Doxorubicin—muscle cancer	0.000128	0.000391	CcSEcCtD
Tacrolimus—Skin disorder—Methotrexate—muscle cancer	0.000127	0.000389	CcSEcCtD
Tacrolimus—Hyperhidrosis—Methotrexate—muscle cancer	0.000127	0.000387	CcSEcCtD
Tacrolimus—PPP3CA—Innate Immune System—MDM2—muscle cancer	0.000126	0.00178	CbGpPWpGaD
Tacrolimus—Malaise—Doxorubicin—muscle cancer	0.000125	0.000383	CcSEcCtD
Tacrolimus—MTOR—NGF signalling via TRKA from the plasma membrane—MDM2—muscle cancer	0.000125	0.00177	CbGpPWpGaD
Tacrolimus—Vertigo—Doxorubicin—muscle cancer	0.000125	0.000382	CcSEcCtD
Tacrolimus—Anorexia—Methotrexate—muscle cancer	0.000125	0.000382	CcSEcCtD
Tacrolimus—Syncope—Doxorubicin—muscle cancer	0.000125	0.000381	CcSEcCtD
Tacrolimus—Leukopenia—Doxorubicin—muscle cancer	0.000124	0.000381	CcSEcCtD
Tacrolimus—PPP3CA—Signaling Pathways—PTCH1—muscle cancer	0.000124	0.00176	CbGpPWpGaD
Tacrolimus—MTOR—Innate Immune System—FOXO4—muscle cancer	0.000124	0.00175	CbGpPWpGaD
Tacrolimus—MTOR—Senescence and Autophagy in Cancer—TP53—muscle cancer	0.000123	0.00174	CbGpPWpGaD
Tacrolimus—Palpitations—Doxorubicin—muscle cancer	0.000123	0.000376	CcSEcCtD
Tacrolimus—Hypotension—Methotrexate—muscle cancer	0.000122	0.000374	CcSEcCtD
Tacrolimus—Loss of consciousness—Doxorubicin—muscle cancer	0.000122	0.000374	CcSEcCtD
Tacrolimus—MTOR—Signaling by NGF—KIT—muscle cancer	0.000122	0.00173	CbGpPWpGaD
Tacrolimus—PPP3CA—Immune System—FOXO1—muscle cancer	0.000122	0.00173	CbGpPWpGaD
Tacrolimus—MTOR—Integrated Breast Cancer Pathway—VEGFA—muscle cancer	0.000122	0.00172	CbGpPWpGaD
Tacrolimus—Cough—Doxorubicin—muscle cancer	0.000121	0.000371	CcSEcCtD
Tacrolimus—Convulsion—Doxorubicin—muscle cancer	0.00012	0.000368	CcSEcCtD
Tacrolimus—Hypertension—Doxorubicin—muscle cancer	0.00012	0.000367	CcSEcCtD
Tacrolimus—Musculoskeletal discomfort—Methotrexate—muscle cancer	0.000119	0.000365	CcSEcCtD
Tacrolimus—MTOR—Adaptive Immune System—FOXO4—muscle cancer	0.000119	0.00168	CbGpPWpGaD
Tacrolimus—Insomnia—Methotrexate—muscle cancer	0.000119	0.000362	CcSEcCtD
Tacrolimus—Arthralgia—Doxorubicin—muscle cancer	0.000118	0.000362	CcSEcCtD
Tacrolimus—Chest pain—Doxorubicin—muscle cancer	0.000118	0.000362	CcSEcCtD
Tacrolimus—Myalgia—Doxorubicin—muscle cancer	0.000118	0.000362	CcSEcCtD
Tacrolimus—FKBP1A—Disease—FOXO4—muscle cancer	0.000118	0.00168	CbGpPWpGaD
Tacrolimus—Anxiety—Doxorubicin—muscle cancer	0.000118	0.000361	CcSEcCtD
Tacrolimus—Paraesthesia—Methotrexate—muscle cancer	0.000118	0.00036	CcSEcCtD
Tacrolimus—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—muscle cancer	0.000118	0.000359	CcSEcCtD
Tacrolimus—ALB—Selenium Micronutrient Network—PTGS2—muscle cancer	0.000117	0.00166	CbGpPWpGaD
Tacrolimus—Discomfort—Doxorubicin—muscle cancer	0.000117	0.000358	CcSEcCtD
Tacrolimus—Dyspnoea—Methotrexate—muscle cancer	0.000117	0.000357	CcSEcCtD
Tacrolimus—Somnolence—Methotrexate—muscle cancer	0.000117	0.000356	CcSEcCtD
Tacrolimus—Dry mouth—Doxorubicin—muscle cancer	0.000116	0.000354	CcSEcCtD
Tacrolimus—Dyspepsia—Methotrexate—muscle cancer	0.000115	0.000353	CcSEcCtD
Tacrolimus—Confusional state—Doxorubicin—muscle cancer	0.000114	0.00035	CcSEcCtD
Tacrolimus—Decreased appetite—Methotrexate—muscle cancer	0.000114	0.000348	CcSEcCtD
Tacrolimus—Anaphylactic shock—Doxorubicin—muscle cancer	0.000113	0.000347	CcSEcCtD
Tacrolimus—Oedema—Doxorubicin—muscle cancer	0.000113	0.000347	CcSEcCtD
Tacrolimus—Gastrointestinal disorder—Methotrexate—muscle cancer	0.000113	0.000346	CcSEcCtD
Tacrolimus—Fatigue—Methotrexate—muscle cancer	0.000113	0.000346	CcSEcCtD
Tacrolimus—Infection—Doxorubicin—muscle cancer	0.000113	0.000345	CcSEcCtD
Tacrolimus—PPP3CA—Disease—FOXO1—muscle cancer	0.000113	0.0016	CbGpPWpGaD
Tacrolimus—Pain—Methotrexate—muscle cancer	0.000112	0.000343	CcSEcCtD
Tacrolimus—Shock—Doxorubicin—muscle cancer	0.000112	0.000341	CcSEcCtD
Tacrolimus—ALB—Hemostasis—ANGPT2—muscle cancer	0.000112	0.00158	CbGpPWpGaD
Tacrolimus—Nervous system disorder—Doxorubicin—muscle cancer	0.000111	0.00034	CcSEcCtD
Tacrolimus—Thrombocytopenia—Doxorubicin—muscle cancer	0.000111	0.00034	CcSEcCtD
Tacrolimus—Tachycardia—Doxorubicin—muscle cancer	0.000111	0.000339	CcSEcCtD
Tacrolimus—Skin disorder—Doxorubicin—muscle cancer	0.00011	0.000337	CcSEcCtD
Tacrolimus—CYP3A4—Tryptophan metabolism—MDM2—muscle cancer	0.00011	0.00156	CbGpPWpGaD
Tacrolimus—Hyperhidrosis—Doxorubicin—muscle cancer	0.00011	0.000335	CcSEcCtD
Tacrolimus—Anorexia—Doxorubicin—muscle cancer	0.000108	0.000331	CcSEcCtD
Tacrolimus—Feeling abnormal—Methotrexate—muscle cancer	0.000108	0.00033	CcSEcCtD
Tacrolimus—Gastrointestinal pain—Methotrexate—muscle cancer	0.000107	0.000328	CcSEcCtD
Tacrolimus—PPP3CA—Signaling Pathways—FOXO4—muscle cancer	0.000107	0.00151	CbGpPWpGaD
Tacrolimus—MTOR—Immune System—CD34—muscle cancer	0.000106	0.0015	CbGpPWpGaD
Tacrolimus—Hypotension—Doxorubicin—muscle cancer	0.000106	0.000324	CcSEcCtD
Tacrolimus—MTOR—Cellular responses to stress—CDKN2A—muscle cancer	0.000106	0.0015	CbGpPWpGaD
Tacrolimus—ALB—Platelet activation, signaling and aggregation—IGF2—muscle cancer	0.000105	0.00149	CbGpPWpGaD
Tacrolimus—PPP3CA—Signaling Pathways—CNR1—muscle cancer	0.000105	0.00149	CbGpPWpGaD
Tacrolimus—CYP3A7—Metabolism—FH—muscle cancer	0.000105	0.00148	CbGpPWpGaD
Tacrolimus—Urticaria—Methotrexate—muscle cancer	0.000104	0.000318	CcSEcCtD
Tacrolimus—Body temperature increased—Methotrexate—muscle cancer	0.000104	0.000317	CcSEcCtD
Tacrolimus—Abdominal pain—Methotrexate—muscle cancer	0.000104	0.000317	CcSEcCtD
Tacrolimus—Musculoskeletal discomfort—Doxorubicin—muscle cancer	0.000103	0.000316	CcSEcCtD
Tacrolimus—Insomnia—Doxorubicin—muscle cancer	0.000103	0.000314	CcSEcCtD
Tacrolimus—MTOR—Cellular responses to stress—MDM2—muscle cancer	0.000103	0.00145	CbGpPWpGaD
Tacrolimus—Paraesthesia—Doxorubicin—muscle cancer	0.000102	0.000312	CcSEcCtD
Tacrolimus—ABCB1—HIF-1-alpha transcription factor network—VEGFA—muscle cancer	0.000102	0.00144	CbGpPWpGaD
Tacrolimus—Dyspnoea—Doxorubicin—muscle cancer	0.000101	0.000309	CcSEcCtD
Tacrolimus—Somnolence—Doxorubicin—muscle cancer	0.000101	0.000308	CcSEcCtD
Tacrolimus—Dyspepsia—Doxorubicin—muscle cancer	9.99e-05	0.000305	CcSEcCtD
Tacrolimus—ALB—Platelet degranulation—VEGFA—muscle cancer	9.94e-05	0.00141	CbGpPWpGaD
Tacrolimus—Decreased appetite—Doxorubicin—muscle cancer	9.87e-05	0.000302	CcSEcCtD
Tacrolimus—Gastrointestinal disorder—Doxorubicin—muscle cancer	9.8e-05	0.0003	CcSEcCtD
Tacrolimus—Fatigue—Doxorubicin—muscle cancer	9.78e-05	0.000299	CcSEcCtD
Tacrolimus—Constipation—Doxorubicin—muscle cancer	9.7e-05	0.000297	CcSEcCtD
Tacrolimus—Pain—Doxorubicin—muscle cancer	9.7e-05	0.000297	CcSEcCtD
Tacrolimus—Hypersensitivity—Methotrexate—muscle cancer	9.66e-05	0.000295	CcSEcCtD
Tacrolimus—FKBP1A—Signaling Pathways—PTCH1—muscle cancer	9.64e-05	0.00136	CbGpPWpGaD
Tacrolimus—MTOR—Signaling by NGF—MDM2—muscle cancer	9.62e-05	0.00136	CbGpPWpGaD
Tacrolimus—ALB—Response to elevated platelet cytosolic Ca2+—VEGFA—muscle cancer	9.47e-05	0.00134	CbGpPWpGaD
Tacrolimus—Asthenia—Methotrexate—muscle cancer	9.4e-05	0.000288	CcSEcCtD
Tacrolimus—Feeling abnormal—Doxorubicin—muscle cancer	9.35e-05	0.000286	CcSEcCtD
Tacrolimus—PPP3CA—Immune System—KIT—muscle cancer	9.3e-05	0.00132	CbGpPWpGaD
Tacrolimus—Gastrointestinal pain—Doxorubicin—muscle cancer	9.28e-05	0.000284	CcSEcCtD
Tacrolimus—Pruritus—Methotrexate—muscle cancer	9.27e-05	0.000284	CcSEcCtD
Tacrolimus—MTOR—Integrated Breast Cancer Pathway—TP53—muscle cancer	9.2e-05	0.0013	CbGpPWpGaD
Tacrolimus—MTOR—Innate Immune System—FOXO1—muscle cancer	9.14e-05	0.00129	CbGpPWpGaD
Tacrolimus—Urticaria—Doxorubicin—muscle cancer	9.02e-05	0.000276	CcSEcCtD
Tacrolimus—Abdominal pain—Doxorubicin—muscle cancer	8.97e-05	0.000274	CcSEcCtD
Tacrolimus—Body temperature increased—Doxorubicin—muscle cancer	8.97e-05	0.000274	CcSEcCtD
Tacrolimus—Diarrhoea—Methotrexate—muscle cancer	8.97e-05	0.000274	CcSEcCtD
Tacrolimus—ABCB1—Allograft Rejection—VEGFA—muscle cancer	8.8e-05	0.00125	CbGpPWpGaD
Tacrolimus—MTOR—Adaptive Immune System—FOXO1—muscle cancer	8.78e-05	0.00124	CbGpPWpGaD
Tacrolimus—ALB—Folate Metabolism—TP53—muscle cancer	8.76e-05	0.00124	CbGpPWpGaD
Tacrolimus—FKBP1A—Disease—FOXO1—muscle cancer	8.74e-05	0.00124	CbGpPWpGaD
Tacrolimus—Dizziness—Methotrexate—muscle cancer	8.67e-05	0.000265	CcSEcCtD
Tacrolimus—PPP3CA—Disease—KIT—muscle cancer	8.59e-05	0.00122	CbGpPWpGaD
Tacrolimus—PPP3CA—Signaling Pathways—IGF2—muscle cancer	8.58e-05	0.00121	CbGpPWpGaD
Tacrolimus—Hypersensitivity—Doxorubicin—muscle cancer	8.36e-05	0.000256	CcSEcCtD
Tacrolimus—Vomiting—Methotrexate—muscle cancer	8.33e-05	0.000255	CcSEcCtD
Tacrolimus—FKBP1A—Signaling Pathways—FOXO4—muscle cancer	8.29e-05	0.00117	CbGpPWpGaD
Tacrolimus—ALB—Metabolism of lipids and lipoproteins—MED12—muscle cancer	8.28e-05	0.00117	CbGpPWpGaD
Tacrolimus—Rash—Methotrexate—muscle cancer	8.26e-05	0.000253	CcSEcCtD
Tacrolimus—Dermatitis—Methotrexate—muscle cancer	8.26e-05	0.000252	CcSEcCtD
Tacrolimus—Headache—Methotrexate—muscle cancer	8.21e-05	0.000251	CcSEcCtD
Tacrolimus—MTOR—Disease—ENO2—muscle cancer	8.17e-05	0.00116	CbGpPWpGaD
Tacrolimus—Asthenia—Doxorubicin—muscle cancer	8.14e-05	0.000249	CcSEcCtD
Tacrolimus—FKBP1A—Signaling Pathways—CNR1—muscle cancer	8.14e-05	0.00115	CbGpPWpGaD
Tacrolimus—Pruritus—Doxorubicin—muscle cancer	8.03e-05	0.000246	CcSEcCtD
Tacrolimus—PPP3CA—Signaling Pathways—FOXO1—muscle cancer	7.89e-05	0.00112	CbGpPWpGaD
Tacrolimus—MTOR—Cellular responses to stress—VEGFA—muscle cancer	7.79e-05	0.0011	CbGpPWpGaD
Tacrolimus—Nausea—Methotrexate—muscle cancer	7.79e-05	0.000238	CcSEcCtD
Tacrolimus—Diarrhoea—Doxorubicin—muscle cancer	7.77e-05	0.000237	CcSEcCtD
Tacrolimus—CYP3A5—Metabolism—FH—muscle cancer	7.57e-05	0.00107	CbGpPWpGaD
Tacrolimus—Dizziness—Doxorubicin—muscle cancer	7.5e-05	0.000229	CcSEcCtD
Tacrolimus—MTOR—Disease—HMGA1—muscle cancer	7.42e-05	0.00105	CbGpPWpGaD
Tacrolimus—PPP3CA—Immune System—MDM2—muscle cancer	7.33e-05	0.00104	CbGpPWpGaD
Tacrolimus—Vomiting—Doxorubicin—muscle cancer	7.22e-05	0.000221	CcSEcCtD
Tacrolimus—MTOR—Immune System—FOXO4—muscle cancer	7.21e-05	0.00102	CbGpPWpGaD
Tacrolimus—Rash—Doxorubicin—muscle cancer	7.16e-05	0.000219	CcSEcCtD
Tacrolimus—Dermatitis—Doxorubicin—muscle cancer	7.15e-05	0.000219	CcSEcCtD
Tacrolimus—Headache—Doxorubicin—muscle cancer	7.11e-05	0.000217	CcSEcCtD
Tacrolimus—MTOR—Innate Immune System—KIT—muscle cancer	6.97e-05	0.000986	CbGpPWpGaD
Tacrolimus—PPP3CA—Disease—MDM2—muscle cancer	6.76e-05	0.000958	CbGpPWpGaD
Tacrolimus—Nausea—Doxorubicin—muscle cancer	6.74e-05	0.000206	CcSEcCtD
Tacrolimus—MTOR—Adaptive Immune System—KIT—muscle cancer	6.69e-05	0.000947	CbGpPWpGaD
Tacrolimus—FKBP1A—Disease—KIT—muscle cancer	6.66e-05	0.000943	CbGpPWpGaD
Tacrolimus—MTOR—Disease—FOXO4—muscle cancer	6.66e-05	0.000942	CbGpPWpGaD
Tacrolimus—FKBP1A—Signaling Pathways—IGF2—muscle cancer	6.65e-05	0.000942	CbGpPWpGaD
Tacrolimus—ALB—Metabolism—FH—muscle cancer	6.52e-05	0.000923	CbGpPWpGaD
Tacrolimus—PPP3CA—Disease—PTGS2—muscle cancer	6.52e-05	0.000923	CbGpPWpGaD
Tacrolimus—FKBP1A—Signaling Pathways—FOXO1—muscle cancer	6.12e-05	0.000867	CbGpPWpGaD
Tacrolimus—PPP3CA—Signaling Pathways—KIT—muscle cancer	6.01e-05	0.000852	CbGpPWpGaD
Tacrolimus—CYP3A7—Metabolism—MED12—muscle cancer	5.92e-05	0.000838	CbGpPWpGaD
Tacrolimus—MTOR—Cellular responses to stress—TP53—muscle cancer	5.88e-05	0.000833	CbGpPWpGaD
Tacrolimus—ABCB1—Integrated Pancreatic Cancer Pathway—MDM2—muscle cancer	5.72e-05	0.00081	CbGpPWpGaD
Tacrolimus—ABCB1—Metabolism—FH—muscle cancer	5.71e-05	0.000809	CbGpPWpGaD
Tacrolimus—ABCB1—Integrated Pancreatic Cancer Pathway—PTGS2—muscle cancer	5.51e-05	0.000781	CbGpPWpGaD
Tacrolimus—MTOR—Innate Immune System—MDM2—muscle cancer	5.49e-05	0.000777	CbGpPWpGaD
Tacrolimus—ALB—Hemostasis—IGF2—muscle cancer	5.42e-05	0.000767	CbGpPWpGaD
Tacrolimus—MTOR—Signaling Pathways—PTCH1—muscle cancer	5.42e-05	0.000767	CbGpPWpGaD
Tacrolimus—CYP3A7—Metabolism—ENO2—muscle cancer	5.4e-05	0.000764	CbGpPWpGaD
Tacrolimus—MTOR—Immune System—FOXO1—muscle cancer	5.32e-05	0.000754	CbGpPWpGaD
Tacrolimus—MTOR—Adaptive Immune System—MDM2—muscle cancer	5.27e-05	0.000746	CbGpPWpGaD
Tacrolimus—FKBP1A—Disease—MDM2—muscle cancer	5.25e-05	0.000743	CbGpPWpGaD
Tacrolimus—FKBP1A—Disease—PTGS2—muscle cancer	5.06e-05	0.000716	CbGpPWpGaD
Tacrolimus—MTOR—Disease—FOXO1—muscle cancer	4.92e-05	0.000696	CbGpPWpGaD
Tacrolimus—PPP3CA—Signaling Pathways—MDM2—muscle cancer	4.74e-05	0.000671	CbGpPWpGaD
Tacrolimus—FKBP1A—Signaling Pathways—KIT—muscle cancer	4.66e-05	0.00066	CbGpPWpGaD
Tacrolimus—MTOR—Signaling Pathways—FOXO4—muscle cancer	4.66e-05	0.00066	CbGpPWpGaD
Tacrolimus—MTOR—Signaling Pathways—CNR1—muscle cancer	4.58e-05	0.000648	CbGpPWpGaD
Tacrolimus—ALB—Platelet activation, signaling and aggregation—VEGFA—muscle cancer	4.41e-05	0.000624	CbGpPWpGaD
Tacrolimus—ABCB1—Integrated Pancreatic Cancer Pathway—VEGFA—muscle cancer	4.34e-05	0.000615	CbGpPWpGaD
Tacrolimus—CYP3A5—Metabolism—MED12—muscle cancer	4.28e-05	0.000606	CbGpPWpGaD
Tacrolimus—MTOR—Immune System—KIT—muscle cancer	4.06e-05	0.000574	CbGpPWpGaD
Tacrolimus—CYP3A5—Metabolism—ENO2—muscle cancer	3.9e-05	0.000552	CbGpPWpGaD
Tacrolimus—MTOR—Disease—KIT—muscle cancer	3.75e-05	0.00053	CbGpPWpGaD
Tacrolimus—MTOR—Signaling Pathways—IGF2—muscle cancer	3.74e-05	0.00053	CbGpPWpGaD
Tacrolimus—ALB—Metabolism—MED12—muscle cancer	3.69e-05	0.000522	CbGpPWpGaD
Tacrolimus—FKBP1A—Signaling Pathways—MDM2—muscle cancer	3.67e-05	0.00052	CbGpPWpGaD
Tacrolimus—PPP3CA—Signaling Pathways—VEGFA—muscle cancer	3.6e-05	0.000509	CbGpPWpGaD
Tacrolimus—CYP3A4—Metabolism—FH—muscle cancer	3.52e-05	0.000498	CbGpPWpGaD
Tacrolimus—MTOR—Signaling Pathways—FOXO1—muscle cancer	3.44e-05	0.000487	CbGpPWpGaD
Tacrolimus—ALB—Metabolism—ENO2—muscle cancer	3.36e-05	0.000476	CbGpPWpGaD
Tacrolimus—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—muscle cancer	3.28e-05	0.000465	CbGpPWpGaD
Tacrolimus—ABCB1—Metabolism—MED12—muscle cancer	3.23e-05	0.000457	CbGpPWpGaD
Tacrolimus—MTOR—Immune System—MDM2—muscle cancer	3.2e-05	0.000452	CbGpPWpGaD
Tacrolimus—MTOR—Disease—MDM2—muscle cancer	2.95e-05	0.000418	CbGpPWpGaD
Tacrolimus—ABCB1—Metabolism—ENO2—muscle cancer	2.94e-05	0.000417	CbGpPWpGaD
Tacrolimus—MTOR—Disease—PTGS2—muscle cancer	2.84e-05	0.000403	CbGpPWpGaD
Tacrolimus—FKBP1A—Signaling Pathways—VEGFA—muscle cancer	2.79e-05	0.000395	CbGpPWpGaD
Tacrolimus—PPP3CA—Signaling Pathways—TP53—muscle cancer	2.72e-05	0.000385	CbGpPWpGaD
Tacrolimus—ALB—Metabolism of lipids and lipoproteins—PTGS2—muscle cancer	2.63e-05	0.000372	CbGpPWpGaD
Tacrolimus—MTOR—Signaling Pathways—KIT—muscle cancer	2.62e-05	0.000371	CbGpPWpGaD
Tacrolimus—ALB—Hemostasis—VEGFA—muscle cancer	2.27e-05	0.000322	CbGpPWpGaD
Tacrolimus—FKBP1A—Signaling Pathways—TP53—muscle cancer	2.11e-05	0.000298	CbGpPWpGaD
Tacrolimus—MTOR—Signaling Pathways—MDM2—muscle cancer	2.07e-05	0.000292	CbGpPWpGaD
Tacrolimus—CYP3A4—Metabolism—MED12—muscle cancer	1.99e-05	0.000282	CbGpPWpGaD
Tacrolimus—CYP3A7—Metabolism—PTGS2—muscle cancer	1.88e-05	0.000266	CbGpPWpGaD
Tacrolimus—CYP3A4—Metabolism—ENO2—muscle cancer	1.81e-05	0.000257	CbGpPWpGaD
Tacrolimus—ALB—Hemostasis—TP53—muscle cancer	1.72e-05	0.000243	CbGpPWpGaD
Tacrolimus—MTOR—Signaling Pathways—VEGFA—muscle cancer	1.57e-05	0.000222	CbGpPWpGaD
Tacrolimus—CYP3A5—Metabolism—PTGS2—muscle cancer	1.36e-05	0.000192	CbGpPWpGaD
Tacrolimus—MTOR—Signaling Pathways—TP53—muscle cancer	1.19e-05	0.000168	CbGpPWpGaD
Tacrolimus—ALB—Metabolism—PTGS2—muscle cancer	1.17e-05	0.000166	CbGpPWpGaD
Tacrolimus—ABCB1—Metabolism—PTGS2—muscle cancer	1.03e-05	0.000145	CbGpPWpGaD
Tacrolimus—CYP3A4—Metabolism—PTGS2—muscle cancer	6.32e-06	8.94e-05	CbGpPWpGaD
